Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

CJC-1295 with DAC

Plain-language summaryIntrigue 65 / 100

CJC-1295 (with DAC) is the long-acting form of the GHRH analog. The DAC (drug affinity complex) binds to plasma albumin, extending the half-life from 30 minutes to about a week. Used in research for sustained growth hormone elevation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Albumin-binding GHRH analog

A long-acting GHRH analog with drug affinity complex (DAC) modification enabling weekly subcutaneous dosing through albumin binding.

Abstract

CJC-1295 with DAC (CJC-1295 long-acting; CAS 863288-34-0) is a modified GHRH 1-29 analog that incorporates a drug affinity complex (DAC) modification (a maleimidopropionyl-Lys side chain) which enables in vivo conjugation to circulating albumin through a covalent linkage with reduced cysteine 34. The albumin conjugation extends plasma half-life from minutes (for sermorelin) to approximately 6 to 8 days, enabling weekly subcutaneous dosing. The compound was developed by ConjuChem (Canada) and reached Phase 2 trials before being discontinued. The non-DAC version of CJC-1295 (without the albumin-binding modification) is the compound covered in our existing CJC-1295 nDAC monograph. The DAC version produces sustained mild GH and IGF-1 elevation rather than the pulsatile pattern of nDAC + GHRP combinations. Doses are 1 to 2 mg subcutaneously per week.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-131Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-DOPA (Levodopa)

Plain-language summaryIntrigue 80 / 100

L-DOPA (levodopa) is the immediate precursor to dopamine and the principal Parkinson disease treatment for over 50 years. It crosses the blood-brain barrier (which dopamine itself cannot) and is converted to dopamine by neuronal enzymes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

46/100

Gold-standard Parkinson’s workhorse with exceptional evidence but almost zero frontier research interest

Look, L-DOPA is about as well-understood as any molecule in clinical pharmacology. The biosynthesis pathway from tyrosine to DOPA to dopamine to norepinephrine has been in every biochemistry textbook since the 1960s, Arvid Carlsson shared a Nobel Prize in 2000 partly for mapping the dopamine deficiency story in Parkinson’s, and carbidopa co-formulation (Sinemet) has been optimized over five decades of clinical use. Thats not a criticism. Its just the reality of where the science stands.

The translational story is as complete as it gets. Multiple phase 3 trials, regulatory approval across essentially every major market, mechanistic confirmation in hundreds of independent labs. The ELLDOPA trial established dose-response relationships. Long-term studies have characterized the motor fluctuation and dyskinesia complications with precision. If what you want is evidence, L-DOPA has more of it than almost any compound in this library. If what you want is an unresolved scientific question to point your lab at, this isnt it.

Here’s where the research conversation actually lives today: continuous intestinal gel delivery systems (Duopa/Duodopa) for reducing off periods, subcutaneous levodopa infusion devices, alpha-synuclein aggregation as an upstream target, LRRK2 inhibition, gene therapy approaches that sidestep the precursor entirely. L-DOPA shows up in that research as a comparator arm or a background medication, not as the compound under investigation. Nobody is running a grant to ask whether L-DOPA works for dopamine-deficient Parkinson’s patients. That question is settled.

We think the bench value is modest but real in a narrow way. If you’re studying dopaminergic circuits, building PD animal models, or interrogating DOPA decarboxylase pharmacology, L-DOPA remains a useful and inexpensive tool. The Mucuna pruriens angle is occasionally cited in supplement literature but adds no meaningful research novelty. As a probe, it’s fine; as a target, there’s essentially nothing left to discover at the level a bench investigator could contribute.

The high evidence and translational scores prevent this from falling into the basement, and honestly that’s appropriate. L-DOPA is important and clinically indispensable. But the Kodiac library exists to surface what’s worth chasing next, and a fully-characterized approved drug that’s been in continuous use for sixty years scores exactly where the rubric puts it: respected, settled, and not the direction we’d point a serious research program.

Novelty

12

Mechanism promise

20

In-category differentiation

48

Evidence quality

88

Translational signal

85

Research bench value

45

Rationale L-DOPA earns high marks on evidence quality and translational signal because it is a definitively effective approved drug with decades of replication, but those same facts make it profoundly uninteresting as a research target: the mechanism is completely mapped, the compound is off-patent and commoditized, and the serious research conversation in dopaminergic biology has moved squarely to managing L-DOPA’s complications rather than L-DOPA itself. No hard cap binds; the raw weighted calculation lands the overall at 46.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dopamine precursor

The immediate precursor of dopamine and the principal pharmacological treatment for Parkinson disease, FDA-approved in combination with carbidopa.

Abstract

L-DOPA (levodopa, L-3,4-dihydroxyphenylalanine; CAS 59-92-7; molecular formula C9H11NO4; molecular weight 197.19) is the immediate precursor of dopamine in the catecholamine biosynthesis pathway. The compound is FDA-approved in combination with carbidopa (Sinemet) or benserazide for Parkinson disease. Carbidopa inhibits peripheral DOPA decarboxylase (which would otherwise convert most administered L-DOPA to dopamine before reaching CNS), enabling effective central dopamine elevation at lower doses with reduced peripheral adverse events. L-DOPA is the principal symptomatic treatment for Parkinson disease and remains the gold standard despite long-term complications including motor fluctuations and dyskinesia. The compound is also extracted naturally from Mucuna pruriens. Doses are highly individualized; typical Sinemet dosing is 25/100 mg three to four times daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-147Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Theobromine

Plain-language summaryIntrigue 45 / 100

Theobromine is the principal alkaloid of cocoa and chocolate. It is structurally similar to caffeine but with weaker stimulant effects and longer duration. The compound is highly toxic to dogs but not humans. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

26/100

Well-characterized food methylxanthine with narrow bench utility beyond the antitussive niche

Look, theobromine is chocolate’s primary methylxanthine, and that sentence basically tells you what you need to know about where it lands on a bench-research priority list. We’ve been studying this compound since the 1840s. Its pharmacology is almost entirely understood. It shares a mechanism class with caffeine (adenosine receptor antagonism, primarily A1 and A2A, plus phosphodiesterase inhibition) but with lower CNS potency and a more pronounced peripheral cardiovascular profile, specifically vasodilation and modest bronchodilation. That longer plasma half-life (7-12 hours versus caffeine’s 3-5 hours) does produce a meaningfully different pharmacokinetic signature, and thats worth noting for experimental design.

Where theobromine earns some genuine credit is in its antitussive biology. Peter Barnes’ group at Imperial College, along with independent replication in the early 2000s, showed that theobromine suppresses cough with efficacy comparable to low-dose codeine, mediated through a sensory nerve-desensitization pathway distinct from typical opioid mechanisms. The compound inhibits depolarization of capsaicin-sensitive vagal afferents at concentrations achievable in real experimental conditions. If you’re building a cough-reflex or airway-sensory research program, theobromine has more bench utility than you’d expect from a food compound, and it’s a cleaner probe here than theophylline.

Outside that niche, the research case is thin. The vasodilation signal is real but characterized to death. The CNS story is mostly “weaker caffeine,” which isn’t a story that motivates an investigator. Some labs have examined theobromine in combination with caffeine, and genuine synergistic interactions do appear, but isolating individual compound contributions is methodologically messy, and most combination literature arrives via industry-funded cocoa extract programs. Not great for drawing clean mechanistic conclusions.

What we dont see here is a novel mechanism, a fresh indication, or an underexplored compound with room for original contribution. The differentiation from caffeine is real but narrow: longer half-life, more peripheral, less central, and a legitimate antitussive probe angle. It’s not that the research is bad, it’s that the interesting questions have largely been answered. A bench investigator setting up a methylxanthine protocol would reach for caffeine or theophylline before theobromine unless that vagal sensory pathway is specifically on their agenda.

Sourcing is trivially easy, stability is fine, handling is unremarkable. None of that matters much when the science doesn’t reward the attention. This is library entry for reference completeness and the narrow antitussive comparison value, not a compound we’d prioritize for an active research program.

Novelty

12

Mechanism promise

18

In-category differentiation

28

Evidence quality

40

Translational signal

35

Research bench value

28

Rationale Novelty and mechanism scores are floored by decades of complete pharmacological characterization in a saturated compound class; a real but narrow antitussive signal from the Barnes group prevents complete dismissal but doesn’t rescue the overall score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine

The principal methylxanthine in cacao with milder CNS effects than caffeine and stronger peripheral vasodilation.

Abstract

Theobromine (3,7-dimethylxanthine; CAS 83-67-0) is the principal methylxanthine in cacao (Theobroma cacao), with smaller amounts in tea. The compound has milder CNS effects than caffeine but stronger peripheral cardiovascular effects (vasodilation, modest blood pressure reduction). Mechanism is the same general class as caffeine (adenosine antagonism, PDE inhibition) but with different relative potencies at the various adenosine receptor subtypes. Pharmacokinetics: plasma half-life 7 to 12 hours (longer than caffeine). Doses are typically 200 to 700 mg from supplements or chocolate. The compound is also notable for toxicity in dogs and other non-human mammals due to slower metabolism.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-163Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Curcumin

Plain-language summaryIntrigue 60 / 100

Curcumin is the principal polyphenol in turmeric. It has potent anti-inflammatory effects via NF-kB inhibition. Oral bioavailability is poor; formulations like phytosomal curcumin and BCM-95 substantially improve absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

27/100

Heavily studied polyphenol with assay-interference problems and weak translational record

Look, curcumin is probably the most studied compound that serious researchers have increasingly stopped trusting. The literature is enormous — tens of thousands of papers over five decades — and thats precisely the problem. A 2017 analysis formally classified curcumin as a PAIN compound (Pan-Assay INterference compound), documenting how it generates false-positive signals across a wide range of biochemical assays through non-specific mechanisms including autofluorescence, thiol reactivity, redox cycling, and metal chelation. A meaningful fraction of the curcumin in vitro signaling literature is artifactual, and the field has been slow to accept that.

The mechanism story reads well on paper: NF-kB inhibition, COX-2 modulation, JAK/STAT interference, Nrf2 activation, kinase targets all over the map. But “many targets” is another way of saying no clean mechanism. What you’re usually seeing is a promiscuous polyphenol interacting with assay components rather than selective engagement with any specific pathway. As a bench probe, curcumin fails the basic requirement of interpretable, reproducible results outside tightly controlled conditions.

The bioavailability situation is real and well-characterized. Free curcumin has oral bioavailability under one percent due to poor aqueous solubility, rapid glucuronidation and sulfation, and extensive first-pass clearance. Enhanced formulations — Meriva (phospholipid complex), Theracurmin (colloidal dispersion), Longvida (SLCP), BCM-95 (essential oil combination) — deliver 7- to 30-fold higher plasma exposure in human PK studies. We’re not dismissing those entirely; Meriva specifically has some legitimate joint-inflammation data from Indena-sponsored trials, and the bioavailability engineering story is at least mechanistically coherent. But effect sizes have been modest and the clinical program hasn’t produced anything that changes what a physician actually does.

Whats genuinely frustrating is the scale of resource investment versus yield. Phase 2 trials in colorectal cancer, IBD, Alzheimer’s disease, and type 2 diabetes have all been run. Results have been largely negative or underwhelming, and the failures are underrepresented in the published record. The registered trial database is more honest about the batting average than PubMed.

We think a serious bench investigator today would default to a more selective NF-kB probe, a cleaner COX-2 inhibitor, or a better-characterized Nrf2 activator before reaching for curcumin. The one legitimate use case is an investigator studying polyphenol pharmacokinetics directly, or validating a bioavailability enhancement platform, where curcumin’s extensive PK history and OTC status make it a convenient reference compound. Outside that narrow lane, the signal-to-noise ratio is genuinely poor and the compound deserves its declining place in serious research programs.

Novelty

18

Mechanism promise

28

In-category differentiation

22

Evidence quality

42

Translational signal

33

Research bench value

25

Rationale Curcumin scores low across novelty, mechanism, and differentiation due to decades-old, well-trodden chemistry and formal PAIN-compound status that undermines a significant fraction of the in vitro literature; the evidence base is enormous in volume but thin in quality, with most registered phase 2 clinical programs returning modest or negative results that rarely reach publication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Turmeric polyphenol

The principal yellow polyphenol of turmeric (Curcuma longa) with broad anti-inflammatory and antioxidant activity but very poor oral bioavailability without enhancement.

Abstract

Curcumin (CAS 458-37-7; molecular formula C21H20O6; molecular weight 368.38) is the principal yellow polyphenol pigment of turmeric (Curcuma longa) rhizome. The compound has broad anti-inflammatory activity (NF-kB inhibition, cyclooxygenase modulation, JAK/STAT modulation), antioxidant activity, and modulation of multiple cancer-related pathways. The principal limitation is poor oral bioavailability: free curcumin shows less than 1 percent oral bioavailability due to extensive first-pass metabolism. Bioavailability-enhanced formulations (Meriva, Theracurmin, Longvida, BCM-95) provide 7- to 30-fold higher plasma exposure and are required for meaningful systemic effects. Doses depend on formulation; standardized 95 percent curcuminoid powder at 1 to 3 grams per day is typical for non-enhanced; enhanced formulations use proportionally lower doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-179Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lithium Carbonate (Low-Dose)

Plain-language summaryIntrigue 75 / 100

Lithium carbonate is the foundational mood stabilizer for bipolar disorder, in clinical use since the 1950s. At low doses (sometimes called microdose lithium, 1-5 mg) it is sometimes used for cognitive support; at standard psychiatric doses (600-1200 mg) it requires blood level monitoring. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Mechanistically interesting GSK-3β probe held back by decades of inconclusive cognitive trial data

Look, lithium is one of the most mechanistically interesting old compounds in psychiatry, and the low-dose cognitive angle is worth understanding even if the overall picture is disappointing. The core mechanism story is solid: lithium inhibits GSK-3β at the magnesium-binding site, meaning it’s non-ATP-competitive and touches tau phosphorylation, Wnt signaling, and neurogenesis in ways that still matter for modern neurodegeneration research. The inositol monophosphatase axis adds a second real target. Two plausible links to Alzheimer’s pathology, both mechanistically grounded. That part we like.

The clinical record is where it falls apart. The LATTICE trial and most of the small MCI studies have come back with effect sizes barely distinguishable from noise. The epidemiological story is actually more interesting: populations with higher trace lithium in drinking water show lower dementia rates in multiple regional analyses from Europe, Japan, and Texas, but those associations are notoriously confounded and nobody has cleanly bridged from ecological correlation to individual-level causation in a powered RCT. The ALS signal, once moderately promising in preclinical models, largely failed to translate across the 2008-2013 trial wave. Thats a real problem for anyone trying to build a research program around the therapeutic case here.

Novelty is the compound’s biggest liability from a research-merit standpoint. Lithium has been in continuous clinical use since the late 1940s, GSK-3β inhibition has been known since the 1990s, and the low-dose cognitive angle has now generated enough inconclusive data that it’s neither fresh territory nor a solved question. It sits in an awkward middle: too old to be exciting, not resolved enough to be instructive. The literature is large but not convergent, and that’s genuinely frustrating.

What we do think is underappreciated is lithium’s bench value as a reference GSK-3β inhibitor. It’s still widely used in cell culture and organoid work precisely because it’s membrane-permeable, hits the target at low concentrations, and has known pharmacokinetics in virtually every model system. More selective inhibitors like CHIR99021 and SB216763 are now the standard where clean single-target readouts matter, but lithium remains useful when you want broad pathway context or need to compare against historical datasets. Its 75-year pharmacology dossier is actually a bench asset.

Honestly, the sourcing reality is fine and the safety profile at sub-therapeutic doses is better characterized than almost any research compound you’ll handle. But neither of those facts makes low-dose lithium more compelling as a primary research target in 2026. The renal and thyroid monitoring requirements add friction without adding signal, and we’re not optimistic that the next cognitive-indication trial cycle produces the clean positive that has eluded the field for two decades. Worth knowing well. Not worth centering a program on.

Novelty

35

Mechanism promise

55

In-category differentiation

42

Evidence quality

48

Translational signal

38

Research bench value

58

Rationale Lithium’s dual GSK-3β and inositol mechanisms are genuinely multi-target and relevant to tau biology, but the low-dose cognitive indication has failed to produce consistent clinical signal across multiple small RCTs, and novelty is severely constrained by 75 years of continuous clinical use. Bench value as a reference GSK-3β inhibitor keeps the score from collapsing further.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mood stabilizer (low-dose)

Prescription lithium carbonate at low doses (150-300 mg) studied for cognitive impairment and dementia prevention.

Abstract

Lithium carbonate (CAS 554-13-2) is the principal lithium salt used clinically since 1949 for bipolar disorder, with approved doses providing 600 to 1800 mg lithium ion per day for mood stabilization. Low-dose lithium (providing 150 to 300 mg lithium ion per day, well below therapeutic mood stabilization range) has been studied for cognitive impairment, Alzheimer disease, and ALS with mixed results; effect sizes are small but mechanistically interesting given lithium’s GSK-3 inhibition and inositol monophosphatase effects. Investigators using low-dose lithium should be aware of the still-narrow therapeutic index and potential renal and thyroid effects with chronic use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-195Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Trazodone

Plain-language summaryIntrigue 64 / 100

Trazodone is an old antidepressant from 1981 that almost nobody uses for depression anymore, because at the doses needed for mood (300 to 600 mg) it is unpleasantly sedating. What it gets prescribed for instead, by enormous margins, is sleep. At 25 to 100 mg it acts as a clean hypnotic by blocking the histamine receptor and the 5-HT2A serotonin receptor, both of which promote arousal. It is non-controlled, has no dependence potential, does not produce the next-day cognitive hangover of older sleep drugs, and is preferred for older adults specifically because it lacks the fall risk of benzodiazepines. The active leftover mCPP is a serotonin receptor activator that occasionally causes brief mood disturbance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

A 45-year-old approved hypnotic with one genuinely interesting neurodegeneration research angle that doesnt move the needle much

Look, trazodone is a compound thats easy to understand and hard to get excited about from a research frontier perspective. Approved by FDA in 1981, its been sitting in the formulary for over four decades as an antidepressant that nobody uses as a first-line antidepressant anymore. What it became is a sleep aid, and thats mostly because its 5-HT2A and H1 antagonism at low dose produces useful sedation without the dependency profile that comes with GABAergic hypnotics. That pharmacological angle is real, well-documented, and thoroughly exhausted as a research question.

The SARI mechanism itself is fine but unremarkable. The weak SERT inhibition (Ki around 160 nM) is why its not competitive with modern SSRIs. The H1 and 5-HT2A hit is why it works as a sleep agent. The active metabolite mCPP is a 5-HT2C agonist that explains some of the anxiogenic side effects some subjects report, and thats a mildly interesting pharmacological wrinkle but again not frontier territory. If you need a 5-HT2A antagonist tool compound, ketanserin is more selective and better characterized for that specific purpose.

Heres the one thing that keeps this from scoring lower than it does. In 2017 Mallucci’s group at the MRC Toxicology Unit published in Brain showing trazodone and dibenzoylmethane could restore protein synthesis in prion disease and other neurodegenerative models by activating eIF2B, essentially bypassing the phospho-eIF2alpha block in the integrated stress response. That finding was not trivial. The ISR pathway is a genuinely active research space for neurodegeneration, and trazodone turned out to be a tool compound for studying it. There’s been follow-up work and some early phase 2 signals in frontotemporal dementia. We think this is real biology. But the evidence base for this specific angle is still small, dominated by that group, and trazodone itself may not be the optimal probe for the ISR pathway going forward.

From a bench utility standpoint, trazodone sits in a weird middle space. Its too well-characterized to be interesting as a novel object of study, but its not indispensable as a research tool the way rapamycin is to mTOR work or ketamine is to NMDA biology. The hypnotic use case is settled science. The ISR angle is interesting but early and contested in terms of whether trazodone is the right vehicle to pursue that biology. What we dont like here is that a serious investigator studying either sleep pharmacology or the ISR pathway would almost certainly reach for different compounds first. The translational signal is solid because its an approved drug that demonstrably works, but that same approval status tells you the research questions around it were answered decades ago.

Novelty

18

Mechanism promise

35

In-category differentiation

28

Evidence quality

68

Translational signal

65

Research bench value

42

Rationale Trazodone scores well on translational signal and evidence because its an approved drug with a massive clinical base, but those same facts kill novelty and differentiation; the one legitimately interesting research angle (ISR/eIF2B activation in neurodegeneration, Mallucci group 2017 Nature) is intriguing but thin on replication and doesnt define a broader research program around trazodone specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin antagonist and reuptake inhibitor (SARI)

A triazolopyridine antidepressant repurposed at low dose as a hypnotic via potent H1 and 5-HT2A antagonism.

Abstract

Trazodone (2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; CAS 19794-93-5; molecular formula C19H22ClN5O; molecular weight 371.86) is a triazolopyridine SARI developed at Angelini and approved by the FDA in 1981. The compound is a weak SERT inhibitor (Ki approximately 160 nM) but a potent 5-HT2A and H1 antagonist (5-HT2A Ki approximately 36 nM, H1 Ki approximately 220 nM). The active metabolite mCPP (m-chlorophenylpiperazine) is a 5-HT2C agonist contributing to anxiogenic side effects in some patients. Pharmacological profile distinguishes trazodone from SSRIs: at antidepressant doses (150 to 600 mg daily) the SERT inhibition contributes meaningfully, but at the more common hypnotic doses (25 to 100 mg) the H1 and 5-HT2A antagonism dominates, producing pronounced sedation without the GABAergic dependency profile of benzodiazepine hypnotics. Plasma half-life is bimodal: 3 to 6 hours alpha phase, 5 to 9 hours beta phase. Adverse events include orthostatic hypotension and the rare but serious priapism (1 in 1000 to 1 in 10000 incidence). Used as a low-dose hypnotic and as a reference compound for 5-HT2A receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-211Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tranylcypromine

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty

18

Mechanism promise

32

In-category differentiation

38

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
BPC-157

Plain-language summaryIntrigue 78 / 100

BPC-157 is a small protein fragment originally isolated from human stomach acid. Researchers found that it speeds up healing of injured tendons, ligaments, muscles, and gut tissue in animal studies. It is one of the most popular peptides in injury recovery research, though human clinical trials are limited. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

44/100

Multi-system repair peptide with real biological interest but single-lab evidence base limits confidence

Look, BPC-157 is one of those compounds where the interesting science and the evidence quality live in completely different zip codes. The 15-residue sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) was pulled from a larger gastric protective protein in human gastric juice, and the Sikiric group at the University of Zagreb spent the better part of three decades building a preclinical record across tendon transection models, gut mucosal protection, vascular reorganization, and dopaminergic modulation. That’s a wide net. Maybe too wide.

What we actually like about the chemistry here is the multi-system profile. VEGF-R2 engagement for angiogenesis, nitric oxide synthase modulation, GH receptor crosstalk, dopaminergic system effects: these aren’t trivial mechanisms to pin on one compound. The oral bioavailability story is genuinely surprising for a 15-amino acid peptide; most sequences this length get destroyed in the gut, and the hypothesis that BPC-157 survives because it evolved as a gut-protective compound is at least coherent. If that holds reliably, it makes BPC-157 unusually interesting as an orally-active probe for tissue repair models, and thats not a small advantage in practice.

The problem is literature provenance. The Sikiric group isn’t just the dominant contributor to BPC-157 research, they’re essentially the entire enterprise. Independent multi-lab replication of the core findings is limited, and when a single research consortium has authored the bulk of the positive preclinical record, you cannot confidently read through the effect sizes and know what’s real versus what’s a lab-specific artifact. We’ve seen this pattern elsewhere: Cerebrolysin has an analogous Eastern European single-consortium problem, and it makes mechanism claims, dose-response estimates, and cross-species generalizations all suspect. Growing replication exists, but we’re not there yet.

Human data is nearly absent. One published Phase 1 single-ascending-dose study is the entire clinical record. No Phase 2 efficacy data, no multi-site trials. The translational arrow points somewhere interesting, but you can’t see how far it reaches from here.

For bench investigators, BPC-157 still has real utility as a probe in tissue repair and gastrointestinal mucosal models. The rodent protocols are well-documented, the peptide synthesizes to high purity, and the multi-system effects give you genuine research surface area. But you’re buying into a single-lab evidence base, and any conclusions you draw need to be treated as hypothesis-generating rather than hypothesis-confirming. Independent replication is what this compound needs more than anything right now, and investigators willing to run that work cleanly would be doing something actually useful for the field. Honest position: compelling enough to study, constrained enough to score modestly.

Novelty

44

Mechanism promise

55

In-category differentiation

50

Evidence quality

28

Translational signal

30

Research bench value

52

Rationale BPC-157 scores modestly on evidence quality (28) and translational signal (30) because the Sikiric group at Zagreb has authored the overwhelming majority of the positive preclinical record, with independent multi-lab replication remaining limited; mechanism and differentiation pull the overall up because the multi-target profile and unexpected oral bioavailability story are genuinely interesting, but the single-consortium provenance prevents the compound from scoring in the established-active range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pentadecapeptide (gastric BPC fragment)

A 15-amino-acid sequence derived from a gastric protective protein, broadly studied in tendon, ligament, vascular, and gut repair models.

Abstract

BPC-157, formally pentadecapeptide BPC 157 (Body Protection Compound 157), is a 15-residue partial sequence isolated from a larger gastric protective protein found in human gastric juice. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0; molecular formula C62H98N16O22; molecular weight 1419.55) was originally characterized in the 1990s by the Sikiric group at the University of Zagreb, who have authored the majority of the published preclinical record. Reported activities span tendon and ligament healing in transection models, vascular reorganization through nitric oxide synthase modulation and VEGF receptor 2 engagement, gastrointestinal mucosal protection, dopaminergic system modulation, and GH receptor crosstalk. Routes studied include intraperitoneal, intramuscular, subcutaneous, oral, and topical administration in rodent models; oral bioavailability is unusual for a peptide of this length and is attributed to the parent compound’s evolutionary role in the gut. Human pharmacokinetic data are sparse; one published Phase 1 single-ascending-dose study has been reported. BPC-157 is not approved by any regulatory authority for human or veterinary use. The literature base is dominated by a single research group, which is the principal limitation on the strength of the evidence; independent replications of the most-cited findings are limited but growing. This monograph reviews the chemistry, mechanism, pharmacokinetics, dosing literature, sourcing risks, and reconstitution practice for in vitro and in vivo investigative work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-002Open in new tab →

Download PDF →

Acquire BPC-157 from the catalog

View BPC-157 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
NAD+

Plain-language summaryIntrigue 70 / 100

NAD+ (nicotinamide adenine dinucleotide) is a cofactor every cell uses for energy production and signaling. NAD+ levels decline with age, driving research interest in supplementation as an anti-aging strategy. Available as injection or supplement. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

38/100

Foundational cellular cofactor with real aging biology, but precursors dominate the research frontier

Cap applied Foundational metabolite cap (max 38)

Look, NAD+ is perhaps the most important small molecule in cellular biology that you’d never call a novel research compound. It’s been known since Arthur Harden’s 1906 Nobel-adjacent work on yeast fermentation, and its three-way role as redox carrier, sirtuin substrate, and PARP feedstock has been textbook material for decades. Scoring a foundational cellular metabolite on research novelty is an odd exercise, but thats exactly what we’re doing, and the answer is honest: NAD+ the molecule doesn’t score well because we already understand it.

The supplementation angle is where things get more interesting, and it’s the reason NAD+ deserves more than a vitamins-and-minerals dismissal. Starting with the Guarente and Sinclair groups’ sirtuin work in the early 2010s, and accelerating through the Imai lab’s 2013 demonstration of age-related NAD+ decline in mice, a serious research community has built up around the depletion-with-aging hypothesis. The biology is real: NAD+ declines substantially in older mammals, SIRT1/SIRT3 activity tracks it, PARP activity rises with DNA damage and competes for the same pool, and CD38 upregulation in aging tissue may be a primary driver of the decline. That’s genuinely interesting territory.

Here’s the problem for this particular product: the direct oxidized free acid is almost never the molecule a serious investigator wants to work with for supplementation research. Poor oral bioavailability means precursors, specifically nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), do essentially everything NAD+ supplementation research needs, more efficiently and with cleaner dose-response curves in animal models. The precursors have the clinical trial basis; they have the Elysium and ChromaDex datasets; they have the longitudinal aging studies. Direct NAD+ infusion has been studied and the acute bioenergetic effects are real, but the programs that matter run on precursors.

What keeps this from scoring lower is bench utility. If you’re running sirtuin deacetylase assays, PARP activity assays, or CD38 kinetics, you need direct NAD+ as a substrate reference. It’s an essential reagent for characterizing the very enzyme systems that make the aging-NAD+ story interesting. That’s real value and we’d never argue otherwise.

As a research compound in the sense this library is built around, NAD+ is foundational background rather than frontier. The investigators doing the interesting work use it as a tool to study the pathways that deplete it, not as the experimental variable. If you’re chasing the sirtuin biology or the CD38 angle, look at precursors and CD38 inhibitors like apigenin or 78c. NAD+ is where the arrows point, not where the interesting questions live.

Novelty

25

Mechanism promise

48

In-category differentiation

30

Evidence quality

60

Translational signal

42

Research bench value

62

Rationale NAD+ is a century-old cofactor with genuine aging-research relevance, but the direct oxidized free acid form is outcompeted by NMN and NR precursors for supplementation research; bench utility as a substrate reference for sirtuin, PARP, and CD38 assays keeps it from bottoming out, but novelty and differentiation anchor the score well below where the aging biology alone might suggest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyridine nucleotide cofactor, redox carrier and substrate for sirtuins, PARPs, and CD38

An obligate intracellular dinucleotide cofactor essential for hundreds of enzymatic reactions, supplied for research use as the oxidized free acid form for parenteral or topical research.

Abstract

Nicotinamide adenine dinucleotide (NAD+; CAS 53-84-9; molecular formula C21H27N7O14P2; molecular weight 663.43) is a small-molecule pyridine dinucleotide cofactor that functions in three biologically distinct roles: as the dominant cellular electron-transfer cofactor in oxidative metabolism (where it cycles between the oxidized NAD+ and reduced NADH forms), as the substrate for the sirtuin family of NAD+-dependent deacetylases (which hydrolyze NAD+ to nicotinamide and ADP-ribose), and as the substrate for poly-ADP-ribose polymerases (PARPs) and the CD38 ecto-enzyme (both of which also consume NAD+). Cellular NAD+ concentrations are tightly regulated and decline substantially with age in humans and other mammals; the age-related decline correlates with reduced sirtuin activity, impaired DNA damage repair, and a constellation of metabolic dysfunctions that has motivated substantial research interest in NAD+ supplementation as a geroprotective intervention. The research-grade product supplied as “NAD+” is the oxidized free acid form, which has poor oral bioavailability but is suitable for parenteral administration in research models. Better-characterized parenteral approaches use NAD+ precursors (nicotinamide riboside NR and nicotinamide mononucleotide NMN), which are more efficiently absorbed orally and converted intracellularly to NAD+. Direct NAD+ administration in research-grade dosing has been used in study of cellular bioenergetics, neurological function, and metabolic endpoints. The compound is not approved by any regulatory authority for human or veterinary use as a therapeutic; NAD+ is also widely available as a food supplement under separate regulatory frameworks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-013Open in new tab →

Download PDF →

Acquire NAD+ from the catalog

View NAD+ →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Epitalon

Plain-language summaryIntrigue 74 / 100

Epitalon is a four-amino-acid peptide developed in Russia by Vladimir Khavinson. The compound is reported to support telomerase activity, the enzyme that maintains the protective caps on chromosomes. Russian research has linked it to longevity in animal studies; Western clinical evidence is limited. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

40/100

Single-lab-dominated telomerase peptide with an interesting premise but no independent replication to back it

Here’s the thing about Epitalon: the scientific story it’s trying to tell is genuinely interesting, but the narrator has a credibility problem. A 4-residue synthetic peptide that modulates telomerase activity and pineal function, potentially slowing biological aging at the cellular level, that’s a real research question worth asking. The problem is that almost every answer in the Epitalon literature comes from the same room in St. Petersburg.

The Khavinson group at the Institute of Bioregulation and Gerontology has produced the overwhelming majority of published work on this compound, beginning in the Soviet era and continuing through to recent years. That’s not automatically disqualifying; single-lab pioneers happen. But when the most-cited claims, telomerase induction in human fibroblasts, lifespan extension in rodent cohorts, melatonin normalization in aging animals, all trace back to the same consortium with limited independent replication, you’re reading a research program, not a scientific consensus. We dont dismiss it; we just cant trust it the way we’d want to.

Mechanistically, there’s something to work with. The telomerase modulation story is plausible at the cell-culture level; the 2009 Nobel for telomere biology validated the broader question even if Epitalon specifically hasnt earned that credibility. The pineal axis angle is interesting too, particularly for circadian biology research. And a small tetrapeptide with reported multi-axis effects gives you some bench flexibility if you’re specifically studying any of those systems. That’s why the bench value score isn’t zero.

What we can’t get past is the evidence layer. The human studies that exist are small, largely uncontrolled observational designs in elderly populations from that same general research context. There’s no multi-center replicated RCT. There’s no independent lab group that has picked this compound up and confirmed the headline findings. The multi-decade literature feels more like one lab’s belief system than a collaborative field.

For investigators who are specifically studying Khavinson-class bioregulator peptides as a category, Epitalon is the canonical reference point and you need to understand it. For anyone studying pineal function or telomere biology more broadly, it’s a secondary reference at best. We’d want to see at least one independent preclinical replication of the telomerase induction findings before putting serious resources behind this compound. Until then, it sits at the interesting-but-untrustworthy tier: worth knowing about, not worth prioritizing over more rigorously evidenced targets in the same longevity space.

Novelty

40

Mechanism promise

55

In-category differentiation

45

Evidence quality

25

Translational signal

30

Research bench value

35

Rationale Epitalon scores in the middle of the single-lab-only range: mechanism novelty is real (telomerase modulation plus pineal axis) but the Khavinson group dominates the literature almost entirely, and the few human studies are uncontrolled small-N observational designs with no independent replication of the headline findings.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide telomerase modulator and bioregulator

A 4-residue synthetic peptide developed in St. Petersburg, studied principally for telomerase modulation, pineal function, and circadian rhythm endpoints in a literature dominated by a single research consortium.

Abstract

Epitalon (also Epithalon, Epithalone; sequence Ala-Glu-Asp-Gly; CAS 307297-39-8; molecular formula C14H22N4O9; molecular weight 390.35) is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues beginning in the 1980s. The compound was designed as a synthetic analog of an active fragment isolated from a bovine pineal gland extract (the original “Epithalamin” preparation) and is reported to modulate pineal melatonin secretion, support telomerase activity in cultured cell lines, and influence circadian gene expression. The published preclinical record is dominated almost entirely by the Khavinson group and affiliated St. Petersburg laboratories, which is the principal methodological concern in any rigorous review of the literature; independent replication of the most-cited findings (telomerase induction, lifespan extension in rodent models) is sparse. A small number of human studies have been published, primarily uncontrolled or small-sample clinical observation studies in elderly populations, which have been critically reviewed for methodological limitations. Reported activities span pineal function modulation, antioxidant effects, telomere length stabilization in cell culture models, and reduction of age-related pathology markers in animal studies. The compound is not approved by any regulatory authority for human or veterinary use outside of certain Russian clinical contexts where Epithalamin (the parent extract) has historical use. Investigators should approach the literature with awareness of the single-laboratory dominance and the limited independent replication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-006Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026

←Previous Page

1 … 65 66 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.